Table 3 Genome-wide significant T2D-ESKD associations (P < 5 × 10−8) in baseline model
Lead variant | CHR | POS | Locus | Effect/other alleles | Stage 1a (1513 T2D-ESKD cases vs. 5299 non-diabetic non-nephropathy controls) | Stage 1b (1700 T2D-ESKD cases vs. 770 non-diabetic non-nephropathy controls) | Stage 1c (219 T2D-ESKD cases vs. 908 non-diabetic non-nephropathy controls) | Stage 2: Meta-analysis (3432 T2D-ESKD cases vs. 6977 non-diabetic non-nephropathy controls) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EAF | OR (95% CI) | P | Info | EAF | OR (95% CI) | P | Info | EAF | OR (95% CI) | P | Info | EAF | OR (95% CI) | P | HetP | |||||
rs72858591 | 2 | 151711452 | RND3/RBM43 | C/T | 0.10 | 1.55 (1.33,1.8) | 1.32E−08 | 0.96 | 0.09 | 1.19 (0.92,1.54) | 0.18 | 0.98 | 0.10 | 1.14 (0.72,1.82) | 0.57 | 0.97 | 0.10 | 1.43 (1.26,1.62) | 4.54E−08 | 0.15 |
rs58627064 | 3 | 165051826 | SLITRK3 | T/G | 0.07 | 1.84 (1.53,2.2) | 4.38E−11 | 0.91 | 0.06 | 1.19 (0.87,1.64) | 0.27 | 0.97 | 0.06 | 1.25 (0.7,2.23) | 0.46 | 1.00 | 0.06 | 1.62 (1.39,1.89) | 6.81E−10 | 0.045 |
rs142563193 | 17 | 77667171 | ENPP7 | A/G | 0.22 | 0.69 (0.6,0.78) | 3.27E−08 | 0.64 | 0.23 | 0.81 (0.68,0.96) | 0.018 | 0.97 | 0.25 | 0.91 (0.66,1.26) | 0.57 | 0.97 | 0.23 | 0.74 (0.67,0.82) | 1.24E−08 | 0.15 |
rs142671759 | 17 | 77706698 | ENPP7 | C/T | 0.03 | 2.82 (2.05,3.87) | 1.53E−10 | 0.73 | 0.02 | 1.15 (0.62,2.12) | 0.66 | 0.82 | 0.02 | 1.53 (0.57,4.13) | 0.40 | 0.92 | 0.02 | 2.26 (1.72,2.97) | 5.53E−09 | 0.029 |
rs4807299 | 19 | 2570002 | GNG7 | A/C | 0.05 | 1.95 (1.58,2.41) | 7.31E−10 | 0.79 | 0.04 | 1.12 (0.76,1.65) | 0.56 | 0.88 | 0.05 | 1.16 (0.58,2.32) | 0.68 | 0.92 | 0.05 | 1.67 (1.4,2) | 3.21E−08 | 0.028 |
rs9622363 | 22 | 36656555 | APOL1 | A/G | 0.46 | 0.78 (0.7,0.85) | 2.55E−07 | 0.87 | 0.44 | 0.77 (0.66,0.89) | 0.00040 | 1.00 | 0.48 | 0.77 (0.58,1.03) | 0.08 | 0.97 | 0.45 | 0.77 (0.72,0.84) | 1.42E−10 | 0.995 |